Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 8/20 | 0.41 |
| ▸ | PPARD | Q03181 | 7/20 | 0.41 |
| ▸ | PPARG | P37231 | 7/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7069902 | 0.79 | ESR1 (0.57) | EPHX1CHRM1ESR1ESR2UBE2N | |
| SCHEMBL7069763 | 0.79 | MEN1 (0.39) | EPHX1PPARAPPARDPPARGCHRM1 | |
| SCHEMBL6715354 | 0.76 | CA12 (0.50) | — | |
| SCHEMBL6934672 | 0.73 | LTA4H (0.46) | PPARAPPARDPPARGLTA4H | |
| SCHEMBL5069498 | 0.72 | LMNA (0.62) | FFAR1 | |
| SCHEMBL1716396 | 0.72 | LDHA (0.65) | EPHX1PPARAPPARGLDHAMMP1 | |
| SCHEMBL27871541 | 0.72 | LDHA (0.60) | EPHX1PPARAPPARGLDHAMMP1 | |
| SCHEMBL29641573 | 0.71 | ITGB3 (0.61) | PPARACHRM1LDHA | |
| SCHEMBL30605287 | 0.71 | ITGB3 (0.61) | PPARACHRM1LDHA | |
| SCHEMBL23494950 | 0.70 | ESR1 (0.63) | PPARAPPARGCHRM1LDHAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | MITSUI CHEMICALS, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1266888-A1 | QUINOLINE DERIVATIVES AND MEDICINAL USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212100-A1 | Quinoline derivatives and medicinal use thereof | PPARG, PPARD, PPARA | EPHX1 2954/4885PPARA 3/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.